Abstract: This invention concerns PAPP-A, its immunodetection and the clinical benefits of such immunodetection. Specifically, the invention includes monoclonal antibodies against PAPP-A and the use of these antibodies to detect PAPP-A at a very early stage of pregnancy. The invention also covers the use of the monoclonal antibodies for the detection of specific types of cancer and Down's Syndrome pregnancies.

Abstract: The present invention is generally directed to the identification of mouse and human genes that inhibit the growth of a tumor and induce apoptosis in cancer cells, and to polypeptides encoded by such genes. In particular, the invention concerns the nucleotide sequence of one such tumor-inhibiting gene, tag7, and the amino acid sequence of a polypeptide encoded by tag7. The invention also provides isolated nucleic acid molecules comprising tag7 polynucleotides, and vectors and host cells comprising these isolated nucleic acid molecules. The invention also provides methods of producing tag7 polypeptides using these nucleic acid molecules, vectors and host cells, tag7 polypeptides made by these methods and antibodies that specifically bind to the tag7 polypeptide. The invention also concerns methods of inhibiting tumor growth and inducing tumor cell apoptosis, and methods of cancer therapy, using the present tag7 nucleic acid molecules and polypeptides.

Abstract: The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.

Abstract: This invention relates to novel humanized and other recombinant or engineered antibodies or monoclonal antibodies to a human .alpha..sub.v subunit-containing heterodimeric integrin receptors and to the genes encoding same. Such antibodies are useful for the therapeutic and/or prophylactic treatment of disorders mediated by such receptors, such as cancer, in human patients.

Abstract: The present invention relates to methods and compositions for enhancing immunological responses and for the prevention and treatment of infectious diseases or primary and metastatic neoplastic diseases based on the administration of macrophages and/or other antigen presenting cells (APC) sensitized with heat shock proteins non-covalently bound to peptide complexes and/or antigenic components. APC are incubated in the presence of hsp-peptide complexes and/or antigenic components in vitro. The sensitized cells are reinfused into the patient with or without treatment with cytokines including but not limited to interferon-.alpha., interferon-.alpha., interleukin-2, interleukin-4, interleukin-6 and tumor neurosis factor.

Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.

Abstract: A method for interfering with the binding between p53 and MDM2 or a protein having a p53 binding site analogous to that of MDM2, which method comprises administering a effective amount of a compound, selected from the group consisting of a peptide having up to twenty eight amino acids which is able to disrupt or prevent binding between p53 and MDM2, or a functional peptide analogue thereof.Compounds for use in the method, methods for detecting such compounds and their application in the diagnosis and treatment of tumors is also described and claimed.

Abstract: Disclosed is the characterization and purification of DNA encoding a numerous polypeptides useful for the stimulation of glial cell (particularly, Schwann cell) mitogenesis and treating glial cell tumors. Also disclosed are DNA sequences encoding novel polypeptides which may have use in stimulating glial cell mitogenesis and treating glial cell tumors. Methods for the synthesis, purification and testing of both known and novel polypeptides for their use as both therapeutic and diagnostic aids in the treatment of diseases involving glial cells are also provided. Methods are also provided for the use of these polypeptides for the preparation of antibody probes useful for both diagnostic and therapeutic use in diseases involving glial cells.

Abstract: Conjugates of chlorophyll (Chl) and bacteriochlorophyll (Bchl) derivatives with amino acids, peptides and proteins are provided by the invention. The amino acid, peptide or protein residue is linked to the 17-propionic acid group of a Chl or Bchl residue directly or through a chain. The conjugates are for use as photosensitizers in photodynamic therapy and in diagnostics of tumors. Conjugation with cell-specific ligands, such as hormones, growth factors or tumor-specific antibodies, will target the Chl or Bchl moiety to the tumor site. Thus, conjugates with melanocyte stimulating hormones are suitable for photodynamic therapy of melanoma tumors.

Abstract: This invention relates generally to the field of immunology, in particular that of antibodies and antibody productions. More specifically, this invention relates to bispecific antibodies, the hybrid hybridomas which produce them, the parent hybridomas, the production and selection of the hybridomas and hybrid hybridomas, and the purification of the bispecific antibodies. Specific examples relate to bispecific monoclonal antibodies which recognize both the human multi-drug resistance antigen, P-glycoprotein and human Fc.gamma. receptor III (hFc.gamma.RIII. These bispecific antibodies are useful in killing cancer cells.

Abstract: A human tumor suppressor gene termed polyhomeotic 2 and its expression products can be used as therapeutic, prognostic, and diagnostic tools for proliferative and developmental disorders. Nucleotide sequences of the gene can also be used to identify a p34.3 region of a human chromosome 1.

Abstract: The present invention relates to methods for cancer diagnosis using a chimeric toxin. In particular, the invention relates to the use of a chimeric toxin composed of gonadotropin releasing hormone (GnRH) and Pseudomonas exotoxin A (PE) to detect a tumor-associated epitope expressed by human adenocarcinomas. Mutated GnRH-PE molecules that bind but do not kill tumor cells are exemplified.

Abstract: An electrode can be derivitized by contacting it with a derivitizing solution to make it more sensitive to a desired analyte signal as opposed to interfering signals in an assay. Particularly, in an electrochemiluminescence (ECL) immunoassay the working electrode can be derivitized to be more sensitive to desired analyte signals, as opposed to interfering non-bound conjugate or serum matrix signals.

Abstract: Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising antibodies and anti-idiotype antibodies that mimic an epitope of antigen that is associated with a tumor or infectious agent. Antibodies and cytokines also may be used to amplify the immune cascade. Moreover, antibodies and anti-idiotype antibodies can be used to produce T cells that are not MHC-restricted and that are targeted to tumor cells and infectious agents.

Abstract: The present invention is related to single and double chain antibodies to EGF receptor. The invention also relates to toxin conjugates of such antibodies. These antibodies are useful for treating and diagnosing the status of pathological conditions such as cancer and cellular hyper proliferation.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed in all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.

Abstract: A radionuclide-chelator conjugate composition for detecting and/or treating lesions in a patient in a pre-targeting protocol which comprises pre-targeting the target cell, tissue, or pathogen with a substrate, using a targeting protein that specifically binds a marker substance on the target cell, tissue, or pathogen and to which the substrate is directly or indirectly bound; parenterally injecting the detection or therapeutic composition of the invention which comprises a chelate conjugate of biotin, a chelator, and a chelatable detection or therapeutic agent, and allowing the composition to accrete at the targeted cell, tissue, or pathogen; wherein the chelate conjugate is purified by chromatography after chelate formation, or further comprises a blood transit-modifying linker or addend that is covalently bound within the chelate conjugate, or both; and using the detection or therapeutic agent to detect or treat the targeted cell, tissue, or pathogen.

Abstract: This invention concerns new PSTPIP polypeptides which are bound by and dephosphorylated by the PEST family of protein tyrosine phosphatases. The invention specifically concerns native murine PSTPIP polypeptides and their homologues in other mammals, and their functional derivatives. The invention further relates to nucleic acids encoding these proteins, vectors containing and capable of expressing such nucleic acid, and recombinant host cells transformed with such nucleic acid. Methods for inducing the polymerization of actin monomers in eukaryotic cells and assays for identifying antagonists and agonists of the PSTPIP polypeptides of the present invention are also provided.

Abstract: A set of contiguous and partially overlapping RNA sequences and polypeptides encoded thereby, designated as PS112 and transcribed from prostate tissue is described. A fully sequenced clone representing a continuous sequence of PS112 is also disclosed. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the prostate, such as prostate cancer. Also provided are antibodies which specifically bind to PS112-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific PS112 polypeptide, which molecules are useful for the therapeutic treatment of prostate diseases, tumors or metastases.

Abstract: The invention discloses methods of inhibiting direct binding of Ras with Raf and screening methods to identify compounds which inhibit direct binding of Ras to Raf, Raf activation, and cell proliferation.